Drug Substance Postapproval Changes Guidance: Determination of Impurity Profile Equivalence

FDA discusses an overview of the assessment of risk factors with respect to the control of impurities and recommendations for documenting the risk-based determination.
Presenter:
Brian Connell, Division of Lifecycle API
Learn more at: www.fda.gov/dr...
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
 
Upcoming Training - www.fda.gov/cd...
SBIA Listserv - public.govdeli...
SBIA 2021 Playlist - • 2021 CDER Small Busine...
SBIA LinkedIn - / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cd...
Twitter - / fda_drug_info  
Email - [e-mail]  
Phone - [phone] I [phone]